Online-Only Supplemental Material

Supplementary Table S1. Participants lipid status over time by lipid category overall and stratified by sex and race/ethnicity

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Dyslipidemia Category** | **Overall****(N=212)** | **Female****(N=144)** | **Male****(N=68)** | **Gender p-value\*** | **NHW****(N=56)** | **AA****(N=91)** | **Hispanic****(N=42)** | **Other****(N=23)** | **Race/ethnicity p-value\*** |
| **HDL-C** |
| Stable normal | 132 (62.3) | 97 (67.4) | 35 (51.5) | 0.1319 | 29 (51.8) | 63 (69.2) | 25 (59.5) | 15 (65.2) | 0.1686 |
| Stable abnormal | 30 (14.2) | 16 (11.1) | 14 (20.6) | 8 (14.3) | 8 (8.8) | 10 (23.8) | 4 (17.4) |
| Progression | 26 (12.3) | 16 (11.1) | 10 (14.7) | 11 (19.6) | 9 (9.9) | 5 (11.9) | 1 (4.3) |
| Regression | 24 (11.3) | 15 (10.4) | 9 (13.2) | 8 (14.3) | 11 (12.1) | 2 (4.8) | 3 (13.0) |
| **LDL-C** |
| Stable normal | 91 (42.9) | 59 (41.0) | 32 (47.1) | 0.2394 | 23 (41.1) | 40 (44.0) | 17 (40.5) | 11 (47.8) | 0.9387 |
| Stable abnormal | 61 (28.8) | 46 (31.9) | 15 (22.1) | 17 (30.4) | 29 (31.9) | 9 (21.4) | 6 (26.1) |
| Progression | 33 (15.6) | 24 (16.7) | 9 (13.2) | 9 (16.1) | 12 (13.2) | 9 (21.4) | 3 (13.0) |
| Regression | 27 (12.7) | 15 (10.4) | 12 (17.6) | 7 (12.5) | 10 (11.0) | 7 (16.7) | 3 (13.0) |
| **Triglycerides** |
| Stable normal | 118 (55.7) | 83 (57.6) | 35 (51.5) | 0.8700 | 28 (50.0) | 67 (73.6) | 13 (31.0) | 10 (43.5) | 0.0002 |
| Stable abnormal | 34 (16.0) | 22 (15.3) | 12 (17.6) | 8 (14.3) | 7 (7.7) | 14 (33.3) | 5 (21.7) |
| Progression | 37 (17.5) | 24 (16.7) | 13 (19.1) | 14 (25.0) | 11 (12.1) | 9 (21.4) | 3 (13.0) |
| Regression | 23 (10.8) | 15 (10.4) | 8 (11.8) | 6 (10.7) | 6 (6.6) | 6 (14.3) | 5 (21.7) |

Data are *n* and (%).

\* p-value from chi-square or Fisher’s exact test evaluating the association of lipid categories with sex and race/ethnicity separately

Non-Hispanic white (NHW), Non-Hispanic black (NHB)

Progression = normal lipid concentration at baseline, abnormal at follow-up

Regression= abnormal lipid concentration at baseline, normal at follow-up

Stable normal= normal lipid concentration at baseline and follow-up

Stable abnormal= abnormal lipid concentration at baseline and follow-up